Clinical Trials
323 trialsNCT05662202 2026-05-22
Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp
Biofrontera Inc.
Phase 3 Active not recruiting
NCT07273656 2026-05-22
TIRBACRYO
University Hospital, Lille
Phase 3 Not yet recruiting
NCT04588246 2026-05-20
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology
Phase 3 Terminated
NCT06568172 2026-05-13
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
National Cancer Institute (NCI)
Phase 3 Suspended
NCT02821013 2026-05-12
STOP-GAP
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT03271372 2026-05-12
ADAM
University of Washington
Phase 3 Active not recruiting
NCT05212246 2026-05-08
B3C
VA Office of Research and Development
Phase 3 Not yet recruiting
NCT06246916 2026-05-06
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT07015190 2026-05-06
Neoadjuvant Darovasertib in Primary Uveal Melanoma
IDEAYA Biosciences
Phase 3 Recruiting
NCT01274338 2026-05-05
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02506153 2026-05-04
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06500455 2026-05-04
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NRG Oncology
Phase 3 Recruiting
NCT05522660 2026-04-27
USZ-STRIKE
ETOP IBCSG Partners Foundation
Phase 3 Recruiting
NCT07552597 2026-04-27
MagMen-II
Vastra Gotaland Region
Phase 3 Not yet recruiting
NCT05352672 2026-04-22
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
Regeneron Pharmaceuticals
Phase 3 Active not recruiting
NCT06585410 2026-04-22
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT07144345 2026-04-22
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
Sun Pharmaceutical Industries Limited
Phase 3 Recruiting
NCT07144852 2026-04-22
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
Sun Pharmaceutical Industries Limited
Phase 3 Recruiting
NCT01682083 2026-04-21
COMBI-AD
Novartis
Phase 3 Completed
NCT06743126 2026-04-21
SUPRAME
Immatics US, Inc.
Phase 3 Recruiting
NCT07530887 2026-04-15
NORMA-2
The Netherlands Cancer Institute
Phase 3 Recruiting
NCT04099251 2026-04-09
CheckMate76K
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT04657991 2026-04-07
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Pfizer
Phase 3 Active not recruiting
NCT05727904 2026-04-03
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Iovance Biotherapeutics, Inc.
Phase 3 Recruiting
NCT06470451 2026-04-03
FLASH2
Soligenix
Phase 3 Recruiting
NCT03969004 2026-03-27
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
Regeneron Pharmaceuticals
Phase 3 Active not recruiting
NCT05907122 2026-03-27
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma
Amgen
Phase 3 Completed
NCT06135415 2026-03-25
TirbAKare
Almirall, S.A.
Phase 3 Completed
NCT02362594 2026-03-05
MK-3475-054
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT06246149 2026-03-04
ATOM
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Recruiting
NCT06007690 2026-03-02
CoMpass
Aura Biosciences
Phase 3 Recruiting
NCT01909453 2026-02-27
COLUMBUS
Pfizer
Phase 3 Completed
NCT06346067 2026-02-27
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Erasca, Inc.
Phase 3 Active not recruiting
NCT00003641 2026-02-25
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT05549297 2026-02-25
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Immunocore Ltd
Phase 3 Recruiting
NCT06587451 2026-02-24
Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®
Sandoz
Phase 3 Terminated
NCT02224781 2026-02-18
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03820986 2026-02-09
LEAP-003
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT07381972 2026-02-02
Photodynamic Therapy Associated With Sonodynamic Therapy for the Treatment of Nodular Basal Cell Carcinoma
University of Sao Paulo
Phase 3 Recruiting
NCT01983748 2026-01-28
Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma
University Hospital Erlangen
Phase 3 Completed
NCT07221734 2026-01-21
Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
mAbxience Research S.L.
Phase 3 Recruiting
NCT06054555 2026-01-12
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
Amgen
Phase 3 Active not recruiting
NCT05002569 2026-01-08
RELATIVITY-098
Bristol-Myers Squibb
Phase 3 Terminated
NCT07311070 2026-01-06
Treatment of Basal Cell Carcinoma (BCC) of the Skin, of the Morpheiform, Infiltrative, and Noduloulcerative Types in Inoperable Patients and Not Suitable for Radiotherapy Using Formulated Methylene Blue
Mashhad University of Medical Sciences
Phase 3 Enrolling by invitation
NCT00133887 2025-12-26
TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients
Hospices Civils de Lyon
Phase 3 Completed
NCT04889118 2025-12-23
LEAP-003
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00799188 2025-12-19
CERTICOEUR
Hospices Civils de Lyon
Phase 3 Completed
NCT03567889 2025-12-17
NeoDREAM
Philogen S.p.A.
Phase 3 Recruiting
NCT06794775 2025-12-12
SWE-NEO
Karolinska University Hospital
Phase 3 Recruiting
NCT04157985 2025-12-11
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
Phase 3 Completed